Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease (AMPLITUDE)

Key Inclusion Criteria:

Part A:

• APOL1 genotype of G1/G1, G2/G2, or G1/G2
• Proteinuric kidney disease

Part B:

- Completion of Treatment Period in Part A and no permanent discontinuation of study drug.

Key Exclusion Criteria:

Part A:

• Solid organ or bone marrow transplant
• Uncontrolled hypertension
• History of diabetes mellitus
• Known underlying cause of kidney disease including but not limited to sickle cell disease

Part B:

• ESKD (End Stage Kidney Disease) as defined in the protocol.
• Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.

Other protocol defined Inclusion/Exclusion criteria will apply.